Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06550518
Status:
COMPLETED
Last Update Posted:
None
First Post:
2021-06-18
Brief Title:
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer EpiTax Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer EpiTax Study
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EPITAX
Brief Summary:
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic especially at a metastatic stage Brain metastasis are identified around 40 to 50 during the evolution of the disease Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment data is lacking more particularly about specific response on brain metastasis
In this retrospective multicentric observational study in real life conditions we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment
In this retrospective multicentric observational study in real life conditions we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None